| pubmed-article:7477432 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C1135183 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0042449 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C1184147 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0205093 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0001455 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0205409 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C2003941 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:7477432 | lifeskim:mentions | umls-concept:C0127400 | lld:lifeskim |
| pubmed-article:7477432 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:7477432 | pubmed:dateCreated | 1995-12-27 | lld:pubmed |
| pubmed-article:7477432 | pubmed:abstractText | The aim of this study was to use a 3H-adenine pre-labelling technique to characterise the effect of alpha 2-adrenoceptor activation on forskolin-stimulated cyclic AMP accumulation in the isolated porcine palmar lateral vein. Forskolin (10(-7)-10(-4) M) stimulated 3H-cyclic AMP accumulation in the isolated porcine palmar lateral vein in a biphasic and concentration-dependent manner. In the absence of the cyclic AMP-selective phosphodiesterase inhibitor rolipram, forskolin stimulated 3H-cyclic AMP accumulation approximately 7-8 fold. The response reached a peak after 5 min. In the presence of rolipram (10(-5) M), basal 3H-cyclic AMP levels were approximately 70% higher than in its absence (basal: 1823 +/- 57 dpm; rolipram: 3088 +/- 229, n = 3) and forskolin (3 x 10(-5) M) stimulated 3H-cyclic AMP accumulation approximately 8 fold. The latter response reached a plateau 10 min after the addition of forskolin. In all subsequent studies, the tissues were incubated with forskolin (3 x 10(-5) M) for 5 min in the absence of rolipram. Noradrenaline (NA; 10(-9)-10(-4) M) and UK14304 (10(-9)-10(-4) M) inhibited forskolin-stimulated 3H-cyclic AMP accumulation in a concentration-dependent manner with mean pIC50 values of 7.61 +/- 0.37 (n = 4) and 7.76 +/- 0.23 (n = 5), respectively. With either NA or UK14304, the maximal inhibition of the forskolin response obtained was approximately 75%. Neither NA (10(-4) M) nor UK14304 (10(-4) M) altered basal 3H-cyclic AMP levels.(ABSTRACT TRUNCATED AT 250 WORDS) | lld:pubmed |
| pubmed-article:7477432 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:language | eng | lld:pubmed |
| pubmed-article:7477432 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:7477432 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:7477432 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:7477432 | pubmed:issn | 0028-1298 | lld:pubmed |
| pubmed-article:7477432 | pubmed:author | pubmed-author:KendallD ADA | lld:pubmed |
| pubmed-article:7477432 | pubmed:author | pubmed-author:WrightI KIK | lld:pubmed |
| pubmed-article:7477432 | pubmed:author | pubmed-author:WilsonV GVG | lld:pubmed |
| pubmed-article:7477432 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:7477432 | pubmed:volume | 352 | lld:pubmed |
| pubmed-article:7477432 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:7477432 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:7477432 | pubmed:pagination | 113-20 | lld:pubmed |
| pubmed-article:7477432 | pubmed:dateRevised | 2010-8-25 | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:meshHeading | pubmed-meshheading:7477432-... | lld:pubmed |
| pubmed-article:7477432 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:7477432 | pubmed:articleTitle | Alpha 2-adrenoceptor mediated inhibition of forskolin-stimulated cyclic AMP accumulation in isolated porcine palmar lateral veins. | lld:pubmed |
| pubmed-article:7477432 | pubmed:affiliation | Department of Physiology and Pharmacology, Medical School, Queen's Medical Centre, Nottingham, UK. | lld:pubmed |
| pubmed-article:7477432 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:7477432 | pubmed:publicationType | In Vitro | lld:pubmed |
| pubmed-article:7477432 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
